ArticleFrontiers in oncology2025
Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify factors influencing recurrence after laparoscopic radical cystectomy for bladder cancer (BC) based on serum levels of miR-18a and miR-122, and to develop and validate a nomogram prediction model. Methods: The relevant information of BC patients who received laparoscopic radical cystectomy procedure in our hospital from January 2021 to October 2022 was collected retrospectively. The patients were divided into a training set and a validation set at a ratio of 7:3 by the complete randomization method. Independent predictive variables included in the Nomogram model were determined and modeled through univariate analysis and multivariate Logistic regression analysis. The receiver operating characteristic curve (ROC) and calibration curves were used to evaluate the predictive efficacy of the model, and decision curve analysis (DCA) was used to evaluate its clinical application value. Results: A total of 280 research subjects were included. Recurrence occurred in 46 (23.47%) of the 196 patients in the training set and 21 (25.00%) of the 84 patients in the validation set. The results of the multivariate logistic regression analysis showed that preoperative serum miR-18a levels, preoperative serum miR-122 levels, postoperative serum carcinoembryonic antigen levels, postoperative serum carbohydrate antigen 19-9 levels, and postoperative antibiotic use duration were significantly associated with recurrence after laparoscopic radical cystectomy for BC. The model was well calibrated and fitted in the training and validation sets. The ROC curve showed that the AUC of the nomogram model to predict postoperative recurrence were 0.796(95% CI: 0.688-0.904) and 0.762(95% CI: 0. 578-0.946), respectively. DCA indicated that the model had clinical application value. Conclusion: The Nomogram model for recurrence after laparoscopic radical cystectomy procedure for BC has good prediction ability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.